

IN THE MATTER OF	*	BEFORE THE
JASMINE SMITH, PHARM TECH	*	STATE BOARD
Registration No.: T13015	*	OF
Respondent	*	PHARMACY
	*	Case No. PT-16-004

* * * * *

ORDER FOR SUMMARY SUSPENSION

Pursuant to Md. State Gov't. (SG) Code Ann. §10-226 (c) (2) (2014 Repl. Vol. II), the State Board of Pharmacy (the "Board") hereby suspends the registration to practice as a Pharmacy Technician (Pharm Tech) in Maryland issued to **JASMINE SMITH**, (the "Respondent"), under the Maryland Pharmacy Act (the "Act"), Md. Health Occ. (H.O.) Code Ann. §§ 12-101 *et seq.* (2014 Repl. Vol. II). This Order is based on the following investigative findings, which the Board has reason to believe are true:

INVESTIGATIVE FINDINGS

1. At all times relevant hereto, the Respondent was registered to practice as a Pharm Tech in Maryland. The Respondent was first registered on July 19, 2013. The Respondent's registration expires on September 30, 2016.

2. At all times relevant hereto, the Respondent was employed as a Pharm Tech at a National chain pharmacy in Harford County, Maryland, hereinafter "Pharmacy A."

3. On or about August 26, 2015, the Board received a Drug Enforcement Administration (DEA) "Report of Theft or Loss of Controlled Substances" notice from Pharmacy A indicating the following:

A. Pharmacy A listed the following drugs as missing/stolen:

Lorazepam ¹ , 0.5 mg	5 tablets
Alprazolam ² , 1 mg	88 tablets
Alprazolam, 2 mg	20 tablets

B. Pharmacy A indicated that the purchase value was \$1;

C. Pharmacy A further indicated that the loss/theft was due to employee pilferage and that the associate stole a few tablets at a time;

4. Furthermore, the Board also received information that, on August 8, 2015, the Pharmacy A's Asset Coordinator was notified by Pharmacy A's Manager that a customer was missing pills from her prescription. The Asset Coordinator reported to Pharmacy A the next day and reviewed video footage which revealed that the Respondent had likely taken the pills based on the actions in the video.

5. The Respondent originally stated to Pharmacy A officials that she had recovered the pills from the trash. When further interviewed, the Respondent admitted, in writing and orally, that she had taken the pills from the prescription and was going to keep them but got scared. She stated that she had, in fact, in the past month taken pills from the pharmacy.

6. As a result, the Respondent was terminated from employment with Pharmacy A.

¹Lorazepam treats anxiety, anxiety with depression, and insomnia (trouble sleeping). This medicine is a benzodiazepine.

²Alprazolam treats anxiety and panic disorder.

CONCLUSIONS OF LAW

Based on the foregoing, the Board finds that the public health, safety or welfare imperatively requires emergency action, pursuant to S.G. §10-226 (c) (2).

ORDER

Based on the foregoing, it is therefore this 9th day of November, 2015, by a majority vote of a quorum of the State Board of Pharmacy, by authority granted to the Board by S.G. §10-226(c) (2), the registration held by the Respondent to practice as a Pharm Tech in Maryland, Registration No. T13015, is hereby **SUMMARILY SUSPENDED**; and be it further

ORDERED that, upon the Board's receipt of a written request from the Respondent, a Show Cause Hearing shall be scheduled within a reasonable time of said request, at which the Respondent will be given an opportunity to be heard as to whether the Summary Suspension should be continued, regarding the Respondent's fitness to practice as a Pharm Tech and the danger to the public; and be it further

ORDERED, that the Respondent shall immediately turn over to the Board her wall certificate and wallet-sized registration to practice as a Pharm Tech issued by the Board; and be it further

ORDERED, that this document constitutes a final Order of the Board and is, therefore, a public document for purposes of public disclosure, as required by Md. Code Ann. Gen. Prov., §§ 4-101 *et seq.*



Laverne G. Naesea, Executive Director
Board of Pharmacy

NOTICE OF HEARING

A Show Cause hearing to determine whether the Summary Suspension shall be continued will be held before the Board at 4201 Patterson Avenue, Baltimore, 21215 following a written request by the Respondent for same.